natgillin/translations-raw huggingface dataset:
250 mg: 20, 30, 50, 60, 100 and multipack of 200 (2 packs of 100) film-coated tablets.
250 mg: 20, 30, 50, 60, 100 i višestruka pakiranja od 200 (2 pakiranja od 100) filmom obloženih tableta.
250 mg: 20, 30, 50, 60, 100 x 1, 100 film-coated tablets and multipacks containing 200 (2 packs of 100) film-coated tablets
250 mg: 20, 30, 50, 60, 100 x 1, 100 filmom obloženih tableta i višestruka pakiranja koja sadrže 200 (2 pakiranja od 100) filmom obloženih tableta
250 microgra ms
250 mikrogram a
250 micrograms (n= 185)
250 mikrograma (n = 185)
250 micrograms (n= 189)
250 mikrograma (n = 189)
250 micrograms (n= 223)
250 mikrograma (n = 223)
250 micrograms of r-hCG or 5,000 to 10,000 IU of hCG, 24 to 48 hours after your last Ovaleap injection.
250 mikrogram r-hCG ili 5000 do 10 000 IU hCG, 24 do 48 sati nakon zadnje injekcije Ovaleapa.
250 micrograms PRE-FILLED SYRINGES LABEL
NALJEPNICA ZA NAPUNJENU ŠTRCALJKU 250 mikrograma
250 micrograms/0.5 mL
250 mikrograma/0,5 ml
250 ml (125 doses
250 ml (125 doza)
250 ml amber glass bottle with a yellow collar on the neck, sealed with a poly-seal cap, and secured with PET film.
Staklena boca od 250 ml, Tip III amber, sa žutim ovratnik na vratu, zapečaćena s poli-kapom i osigurana PET filmom.
250 ml oral solution 500 ml oral solution
250 ml oralne otopine 500 ml oralne otopine
250 ml Sodium Chloride 9 mg/ml (0.9%)
250 ml natrijevog klorida 9 mg/ml (0,9%)
250 ml) final
250 ml otopine)
250 mL, at a free flowing rate to flush the vein.
250 mL uz slobodan protok kako bi se vena isprala.
250 pigs with an average bodyweight of 20 kg).
250 svinja prosječne tjelesne mase 20 kg).
250 times the recommended dose) produced emesis, defecation, drooped eyes, trembling and quietness.
250 puta veća doza od preporučene) uzrokovale su emezu, defekaciju, ptozu očnih kapaka, drhtanje i povučenost.
250 µg
250 µg)
250 µg in 0.5 ml
250 µg u 0,5 ml
250 – 450 mg
250-450 mg
2500 doses
2500 doza
250mg n=152
250 mg n=152
252 tablets
252 tablete
252 x 1 capsules (unit dose)
252 x 1 kapsule (dozna jedinica)
252.0 micrograms
252,0 mikrograma
254 patients with normal hepatic function (total bilirubin ≤ULN and AST ≤ULN), ceritinib exposures were similar in patients with mild hepatic impairment and normal hepatic function.
254 bolesnika s normalnom jetrenom funkcijom (ukupni bilirubin ≤GGN i AST ≤GGN), izloženosti ceritinibu bile su slične u bolesnika s blagim oštećenjem jetre i normalnom jetrenom funkcijom.
254, Avenue Marcel Mérieux-69007 Lyon FRANCE
254, Avenue Marcel Mérieux-69007 LYON FRANCUSKA
255 patients who received docetaxel in combination with capecitabine.
255 bolesnika koji su primali docetaksel u kombinaciji s kapecitabinom,
256 mg dinotefuran,
256 mg dinotefurana,
256 patients were randomised to treatment with docetaxel alone (100 mg/ m2 as a 1 hour intravenous infusion every 3 weeks).
Za liječenje docetakselom u monoterapiji (100 mg/m2 u obliku jednosatne intravenske infuzije svaka 3 tjedna) bilo je randomizirano 256 bolesnika.
256 patients were randomised to treatment with docetaxel alone (100 mg/m2 as a 1 hour intravenous infusion every 3 weeks).
Samo docetaksel (100 mg/m2 u jednosatnoj intravenskoj infuziji svaka 3 tjedna) primalo je slučajnim odabirom 256 bolesnica.
256 patients were randomised to treatment with docetaxel alone (100 mg/m2 as a 1 hour intravenous infusion every 3 weeks).
Za liječenje docetakselom u monoterapiji (100 mg/m2 u obliku jednosatne intravenske infuzije svaka tri tjedna) bilo je randomizirano 256 bolesnika.
256 patients were randomised to treatment with docetaxel alone (100 mg/m² as a 1 hour intravenous infusion every 3 weeks).
Za liječenje docetakselom u monoterapiji (100 mg/m2 u obliku jednosatne intravenske infuzije svaka 3 tjedna) bilo je randomizirano 256 bolesnika.
258 patients who received docetaxel in combination with doxorubicin.
258 bolesnika koji su primali docetaksel u kombinaciji s doksorubicinom,
259
Gradus 2
25–75 percentile (months)
25. – 75. percentil (mjeseci)
26 (21, 32)
OBT (N=237)
26 August 2013
26. kolovoza 2013.
26 March 2001 / 24 April 2006
26. ožujka 2001. / 24. travnja 2006.
26 mL solution in a type I glass 30 mL vial closed with a coated butyl rubber stopper.
26 ml otopine u bočici od 30 ml, izrađenoj od stakla tipa I i zatvorenoj obloženim čepom od butilne gume.
26 relevant cases with positive dechallenge after discontinuation or dose reduction or positive rechallenge were identified.
26 relevantnih slučajeva u kojima se štetni događaj povukao nakon prestanka uzimanja ili smanjenja doze (positive dechallenge) ili u kojima se štetni događaj ponovo javio nakon ponovnog uzimanja lijeka (positive rechallenge).
26 relevant cases with positive dechallenge after discontinuation or reduction of dose or positive dechallenge were identified.
26 relevantnih slučajeva u kojima se štetni događaj povukao nakon prestanka uzimanja ili smanjenja doze (positive dechallenge) ili u kojima se štetni događaj ponovo javio nakon ponovnog uzimanja lijeka (positive rechallenge).
26 Rue de la Chapelle 68330 Huningue FRANCE
26 Rue de la Chapelle F-68330 Huningue FRANCUSKA
26 Rue de la Chapelle F-68330 Huningue France
26 Rue de la Chapelle F-68330 Huningue Francuska
26 week endpoint
26 tjedana
26 week endpoint
Ishod nakon 26 tjedana
26 weeks of treatment
26 tjedana liječenja
26, Rue de la Chapelle 68330 Huningue France
26, Rue de la Chapelle 68330 Huningue Francuska
26,167 unvaccinated Aged ≥7 months Received 3 doses
26 167 necijepljenih U dobi od ≥7 mjeseci Primilo 3 doze
26.2, 303.2
Odgovor CTN-a
26.2L/min p<0.001 (18.0, 34.3)
26,2 l/min p<0,001 (18,0; 34,3)
26.3% (study US301).After 12 months with active treatment, the ACR response rates in leflunomide patients were 52.3% (studies MN301/303), 50.5% (study MN302) and 49.4% (study US301), compared to 53.8% (studies MN301/303) in sulphasalazine patients, 64.8% (study MN302), and 43.9% (study US301) in methotrexate patients.
Nakon 12 mjeseci aktivnog liječenja stopa odgovora prema ACR-u u bolesnika koji su primali leflunomid bila je 52,3% (studije MN301/303), 50,5% (studija MN302) i 49,4% (studija US301) u usporedbi s 53,8% (studije MN301/303) u bolesnika koji su primali sulfasalazin te 64,8% (studija MN302) i 43,9% (studija US301) u bolesnika koji su primali metotreksat.
26.4% (20.9 to 32.4)
26,4% (20,9 do 32,4)
26.4% (n = 78) (95% CI: 21.4%, 31.5%) (10.8% CR, 15.6% PR)
26,4% (n = 78) (95% CI: 21,4%; 31,5%) (10,8% CR, 15,6% PR)
26.5 (19.4, 35.8)
MPR+R vs MPp+p
26.5 [18.98, 34.05] (n = 132)
35% (29,7; 39,5)
26.8 mcg/ml (SD ± 17.45) in Crohn’s disease.
± 15,51) kod ulceroznog kolitisa i 26,8 µg/ml (SD ± 17,45) kod Crohnove bolesti.
26.9% ; 17.4%
ekundarni toničko-klonički
26.9% ; 17.4%
Zonisamid
2621 North Belt Highway, St. Joseph,
2621 North Belt Highway, St.
2630 Taastrup Denmark
2630 Taastrup Danska
2630 Taastrup, Denmark.
2630 Taastrup, Danska
265
ADCS-IADL
268 mg fipronil,
fipronil 268 mg, (S)-metopren 241,2 mg, amitraz
27 (13)b
1 (< 1)
27 to 32) on Day 25, adjust the dose based on the Day 10 Na⁺/K⁺ ratio using the guidelines in Table 1, below.
27 do 32) na 25. dan, prilagodite dozu na temelju Na⁺/K⁺ omjera, na 10. dan pomoću smjernica iz Tabele 1, ovdje ispod.
27 to 32) on Day 25, adjust the dose based on the Day 10 Na⁺/K⁺ ratio using the guidelines in Table 1, below.
27 do 32) na 25. dan, prilagodite dozu na temelju Na⁺/K⁺omjera na 10. dan pomoću smjernica iz Tabele 1, ovdje ispod.
27 to < 29
27 do < 29
27.0 (7.6)
Min ; Maks
27.0 mo (24.7, 31.1)
(24,7; 31,1)
27.0 mo (24.7, 31.1)
27,0 mjeseci (24,7; 31,1)
27.0 to 28.8
27,0 do 28,8
27.0 vs.
27,0 naspram 8,0
27.2 (25.95; NE)
27,2 (25,95; NP)
27.3 to 89.3
27,3 do 89,3
27.5
LOCF
27.5 micrograms/spray
mikrograma/potisak
27.5%
30. tjednua
270 hard capsules
270 tvrdih kapsula
270 tablets
270 tableta
270 tablets: EU/1/09/579/011
270 tableta: EU/1/09/579/011
270 tablets: EU/1/09/579/017
270 tableta: EU/1/09/579/017
270 tablets: EU/1/09/580/005
270 tableta: EU/1/09/580/005
270 tablets: EU/1/09/580/011
270 tableta: EU/1/09/580/011
270 tablets: EU/1/09/580/017
270 tableta: EU/1/09/580/017
270 units*
270 jedinica*.
270 units*.
270 jedinica*.
27100 – Pavia Italy
27100 – Pavia Italija
27460 Igoville France
27460 Igoville Francuska
27472 Cuxhaven Germany
27472 Cuxhaven Njemačka
2750 Ballerup Denmark
2750 Ballerup Danska
28 (4x7) pre-filled syringes (multipack)
28 (4x7) napunjenih štrcaljki (višestruko pakiranje)
28 August 2015
28 Kolovoz 2015
28 buccal tablets
28 bukalnih tableta
28 capsules
140 kapsula
28 capsules of Lojuxta 10 mg
28 kapsula lijeka Lojuxta 10 mg
28 capsules of Lojuxta 20 mg
28 kapsula lijeka Lojuxta 20 mg
28 capsules of Lojuxta 30 mg
28 kapsula lijeka Lojuxta 30 mg
28 capsules of Lojuxta 40 mg
28 kapsula lijeka Lojuxta 40 mg
28 capsules of Lojuxta 5 mg
28 kapsula lijeka Lojuxta 5 mg
28 capsules of Lojuxta 60 mg
28 kapsula lijeka Lojuxta 60 mg
28 coated tablets
28 obloženih tableta
28 day pack containing:
Pakiranje za 28 dana sadržava:
28 day pack: 112 capsules (4 blister cards of 21 x 20 mg capsules and 7 x 80 mg capsules) for the 140 mg daily dose for a 28 day supply.
Pakiranje za 28 dana: 112 kapsula (4 blister kartice od: 21 x 20 mg i 7 x 80 mg) za dnevnu dozu od 140 mg za primjenu tijekom 28 dana.
28 day pack: 56 capsules (4 blister cards of 7 x 20 mg capsules and 7 x 80 mg capsules) for the 100 mg daily dose for a 28 day supply.
Pakiranje za 28 dana: 56 kapsula (4 blister kartice od: 7 x 20 mg i 7 x 80 mg) za dnevnu dozu od 100 mg za primjenu tijekom 28 dana.
28 day pack: 84 capsules (4 blister cards of 21 x 20 mg capsules) for the 60 mg daily dose for a 28 day supply.
Pakiranje za 28 dana: 84 kapsule (4 blister kartice od: 21 x kapsula od 20 mg) za dnevnu dozu od 60 mg za primjenu tijekom 28 dana.
28 days after first opening.
28 dana nakon prvog otvaranja
28 Days after inactivated vaccinea
28 dana nakon primjene inaktiviranog cjepivaa
28 days of treatment with Quinsair 240 mg twice daily followed by 28 days off treatment).
28 dana liječenja Quinsairom 240 mg dva puta na dan nakon čega je slijedilo 28 dana bez terapije).
28 Feb 2021
28. veljače 2021.
28 film-coated tablets
28 filmom obloženih tableta.
28 film-coated tablets
56 x 1 filmom obloženih tableta
28 film-coated tablets
filmom obložene tablete
28 film-coated tablets (calendar blister)
28 filmom obloženih tablet (kalendarski blister)
28 film-coated tablets 30x1 film-coated tablets 90x1 film-coated tablets 98 film-coated tablets
90 x 1 filmom obložena tableta 98 filmom obloženih tableta
28 hard capsules: EU/1/09/525/008 30 hard capsules: EU/1/09/525/009 56 hard capsules: EU/1/09/525/010 60 hard capsules: EU/1/09/525/011 112 hard capsules: EU/1/09/525/012 200 hard capsules: EU/1/09/525/048 250 hard capsules: EU/1/09/525/013
28 tvrdih kapsula: EU/1/09/525/008 30 tvrdih kapsula: EU/1/09/525/009 56 tvrdih kapsula: EU/1/09/525/010 60 tvrdih kapsula: EU/1/09/525/011 112 tvrdih kapsula: EU/1/09/525/012 200 tvrdih kapsula: EU/1/09/525/048 250 tvrdih kapsula: EU/1/09/525/013
28 hard capsules: EU/1/09/525/014 30 hard capsules: EU/1/09/525/015 56 hard capsules: EU/1/09/525/016 60 hard capsules: EU/1/09/525/017 112 hard capsules: EU/1/09/525/018 200 hard capsules: EU/1/09/525/049 250 hard capsules: EU/1/09/525/019
28 tvrdih kapsula: EU/1/09/525/014 30 tvrdih kapsula: EU/1/09/525/015 56 tvrdih kapsula: EU/1/09/525/016 60 tvrdih kapsula: EU/1/09/525/017 112 tvrdih kapsula: EU/1/09/525/018 200 tvrdih kapsula: EU/1/09/525/049 250 tvrdih kapsula: EU/1/09/525/019
28 hard capsules: EU/1/09/525/020 30 hard capsules: EU/1/09/525/021 56 hard capsules: EU/1/09/525/022 60 hard capsules: EU/1/09/525/023 112 hard capsules: EU/1/09/525/024 200 hard capsules: EU/1/09/525/050 250 hard capsules: EU/1/09/525/025
28 tvrdih kapsula: EU/1/09/525/020 30 tvrdih kapsula: EU/1/09/525/021 56 tvrdih kapsula: EU/1/09/525/022 60 tvrdih kapsula: EU/1/09/525/023 112 tvrdih kapsula: EU/1/09/525/024 200 tvrdih kapsula: EU/1/09/525/050 250 tvrdih kapsula: EU/1/09/525/025
28 IU / mg).
28 IJ/mg).
28 IU / mg).
28 IU/mg).
28 July 2009
28.07.2009.
28 mcg/day via continuous infusion
28 µg/dnevno putem kontinuirane infuzije
28 mg (0.3 ml) twice daily
28 mg (0,3 ml) dva puta na dan
28 mg per kilogram body weight for patients receiving regular blood transfusions,
28 mg po kilogramu tjelesne težine za bolesnike koji primaju redovite transfuzije krvi,
28 mg/kg/day
28 mg/kg/dan
28 out of 40 (70%) subjects achieved SVR12: 22/33 (73%) with HCV genotype 1 infection, 6/6 (100%) with HCV genotype 3 infection, and 0/1 (0%) with HCV genotype 4 infection.
Dvadeset i osam od 40 (70%) ispitanika postiglo je SVR12: 22/33 (73%) s infekcijom HCV-om genotipa 1, 6/6 (100%) s infekcijom HCV-om genotipa 3 i 0/1 (0%) s infekcijom HCV-om genotipa 4.
28 patches
28 flastera
28 pre-filled syringes with solvent
28 napunjenih štrcaljki s otapalom
28 sublingual tablets
28 sublingvalnih tableta
28 tablet box, 84 tablet box
kutija s 28 tableta, kutija s 84 tablete
28 tablets
) 28 tableta
28 tablets
28 tablete
28 tablets
EU/1/09/566/004
28 tablets
tableta
28 tablets (PA/Alu/PVC blisters)
28 tableta (PA/Al/PVC blisteri)
28 tablets (PVC/PCTFE blisters)
28 tableta (PVC/PCTFE blisteri)
28 tablets in blister packs Paper/Aluminium/Nylon/Aluminium/PVC.
28 tableta u papir/aluminij/najlon/aluminij/PVC blister pakiranju od -.
28 tablets in blister packs Paper/Aluminium/Nylon/Aluminium/PVC.
28 tableta u papir/aluminij/najlon/aluminij/PVC blister pakiranju.
28 tablets: EU/1/08/480/002
28 tableta: EU/1/08/480/002
28 tablets: EU/1/10/632/002
28 tableta: EU/1/10/632/002
28 tablets: EU/1/10/632/009
28 tableta: EU/1/10/632/009
28 tablets: EU/1/10/632/016
28 tableta: EU/1/10/632/016
28 tablets: EU/1/11/721/002
28 tableta: EU/1/11/721/002
28 tablets: EU/1/11/721/009
28 tableta: EU/1/11/721/009
28 tablets: EU/1/11/721/016
28 tableta: EU/1/11/721/016
28 tablets: EU/1/11/723/002
28 tableta: EU/1/11/723/002
28 tablets: EU/1/11/723/009
28 tableta: EU/1/11/723/009
28 tablets: EU/1/11/723/016
28 tableta: EU/1/11/723/016
28 to less than 40
od 28 do manje od 40
28 transdermal patches
28 transdermalnih flastera
28 vials with 5 mg teduglutide as a powder
28 bočica s 5 mg teduglutida u obliku praška
28 x 1 capsules (unit
28 x 1 kapsula
28 x 1 film-coated tablets
28 x 1 filmom obložena tableta
28 x 1 film-coated tablets
28 x 1 filmom obloženih tableta
28 x 1 film-coated tablets
56 × 1 filmom obložena tableta
28 x 1 film-coated tablets
98 x 1 filmom obložena tableta
28 x 1 tablet (unit dose)
28 x 1 tableta (jedinična doza)
28 x 1 tablet (unit dose)
28 x1 tableta (jedinična doza)
28 x 1 tablets (unit
28 x 1 tableta
28 x 1 tablets (unit
7 x 1 tableta
28 x 1 tablets (unit dose)
28 x 1 tableta (jedinična doza)
28 x 10 capsules + 2 inhaler
28 x 10 kapsula + 2 inhalatora
28% of patients treated with OZURDEX had a ≥ 10 mm Hg IOP increase from baseline at one or more visits during the study.
28 % bolesnika liječenih lijekom OZURDEX imalo je porast IOT-a ≥ 10 mm Hg u odnosu na početne vrijednosti na jednom ili više pregleda tijekom ispitivanja.
28-Day Cycles 1 & 2
1. i 2.
28-Day Cycles 3+
28-dnevni ciklus
28.0% (13.3, 42.6) p=0.0004
28.0% (13,3; 42,6)
28.2L/min p<0.001 (21.7, 34.8)
28,2 l/min p<0,001 (21,7; 34,8)
28.3 mg/tablet
28.3 mg/tableta
28.9 to 30.6
28,9 do 30,6
280 (20 x 14) tablets (multipack)
280 (20 x 14) tableta (višestruko pakovanje)
280 tablets
280 tableta
280 tablets (20x14, PVC/PCTFE blisters)
280 tableta (20x14, PVC/PCTFE blisteri)
280 x 1 film-coated tablet (unit dose)
280 x 1 filmom obloženih tableta (jedinična doza)
28108 Madrid Spain
28108 Madrid Španjolska
286 subjects received two doses and 9 subjects received only one dose.
286 ispitanika primilo je dvije doze, dok je 9 ispitanika primilo samo jednu dozu.
28760 Madrid (SPAIN)
28760 Madrid (ŠPANJOLSKA)
28760 Madrid SPAIN
28760 Madrid ŠPANJOLSKA
28770 Colmenar Viejo (Madrid) Spain
28770 Colmenar Viejo (Madrid) Španjolska
2881 Route des Crêtes, Z.I. Les Bouilides-Sophia Antipolis, 06560 Valbonne - France
2881 Route des Crêtes, Z.I. Les Bouilides-Sophia Antipolis, 06560 Valbonne - Francuska
289 (46.0%) ng/mL and 2,310 (43.5%) ng•h/mL in subjects with moderate hepatic impairment, and 305 (24.8%) ng/mL and 2,740 (44.0%) ng•h/mL in subjects with severe hepatic impairment.
289 (46,0%) ng/ml i 2.310 (43,5%) ng•h/ml u ispitanika s umjerenim oštećenjem jetre te 305 (24,8%) ng/ml i 2.740 (44,0%) ng•h/ml u ispitanika s teškim oštećenjem jetre.
28x1 film-coated tablets
28x1 filmom obloženih tableta
28x1 tablets (unit dose)
28x1 tableta (jedinična doza)
29 %
svi
29 (0.04)
(g/l)
29 Avenue Tony Garnier 69007 Lyon
29, avenue Tony Garnier
29 Avenue Tony Garnier 69007 Lyon
29, avenue Tony Garnier 69007 Lyon
29 avenue Tony Garnier 69007 Lyon,
29 avenue Tony Garnier 69007 Lyon
29 Avenue Tony Garnier 69007 LYON,
29, avenue Tony Garnier
29 Avenue Tony Garnier F-69007 Lyon
29, avenue Tony Garnier F-69007 Lyon
29 avenue Tony Garnier F-69007 LYON FRANCE
29 avenue Tony Garnier F-69007 LYON FRANCUSKA
29 completers achieved a 20% or greater reduction of parenteral nutrition.
Šesnaestoro (55,2%) od 29 ispitanika koji su završili ispitivanje postiglo je 20% ili veće smanjenje parenteralne prehrane.
29 November 2010
29. studenog 2010.
29 route des Industries 37530 Pocé-sur-Cisse France
29 route des Industries 37530 Pocé-sur-Cisse Francuska
29 to < 32
29 do < 32
29% (n = 209)
15% (n = 209)
29% had locally advanced prostate cancer
29% s lokalno uznapredovalim karcinomom prostate
29, Avenue Tony Garnier 69007 Lyon
29, Avenue Tony Garnier
29.6 days or a 66% reduction, p<0.0001).
29,6 dana ili smanjenje za 66%, p<0,0001).
29.6 to 36.1
29,6 do 36,1
29.6)
N=69
29.7% (docetaxel alone); p = 0.0058. Time to progressive disease was superior in the capecitabine + docetaxel combination arm (p<0.0001).
Vrijeme do progresije bolesti bilo je duže u skupini koja je liječena kombinacijom kapecitabina i docetaksela (p<0,0001).
29.7% (docetaxel alone); p = 0.0058. Time to progressive disease was superior in the docetaxel + capecitabine combination arm (p < 0.0001).
Vrijeme do progresije bolesti je bilo dulje u skupini koja je primala kombinaciju docetaksel + kapecitabin (p<0,0001).
29/57
maksimalnim
290 micrograms
290 mikrograma
290–1000 U1
290 – 1000 U1
293 cells/mm3 in the ATV/r+FTC/TDF-treated patients.
280 stanica/mm³ u pacijenata liječenih Stribildom i 293 stanice/mm³ u pacijenata liječenih ATV/r + FTC/TDF-om.
294 (3x98) tablets (multipack)
294 (3x98) tableta (višestruko pakiranje)
294 tablets
294 tableta
294 tablets: fourteen transparent calendar blisters of 21 tablets each.
294 tablete: četrnaest prozirnih kalendarskih blistera, svaki s 21 tabletom.
2970 Hørsholm Denmark or
2970 Hørsholm Danska ili
298.0
titar (1/dil)
2: adverse reactions noted with increased frequency when bexarotene was administered at a dose of 300 mg/m2/day in non-CTCL cancer patients.
2: nuspojave zabilježene povećanom učestalošću kad se beksaroten primjenjivao u dozi od 300 mg/m2 na dan u onkoloških bolesnika bez CTCL-a.
2: December
2019.
2: For further description, please see sub-section “Description of selected adverse reactions”
2 Za dodatni opis, molimo pogledajte odlomak „Opis izabranih nuspojava“
2: most cases of hepatic function abnormal / liver disorder from post-marketing experience with telmisartan occurred in Japanese patients.
2: većina slučajeva abnormalne jetrene funkcije/poremećaja jetre iz iskustva nakon stavljanja lijeka u promet u vezi s telmisartanom se javilo kod Japanskih bolesnika.
2: most cases of hepatic function abnormal / liver disorder from post-marketing experience with telmisartan occurred in Japanese patients.
2: većina slučajeva poremećene jetrene funkcije/poremećaja jetre iz iskustva nakon stavljanja lijeka u promet u vezi s telmisartanom se javilo kod japanskih bolesnika.
2: Plunger head
2: glava klipa
2adjuvanted by AS04 containing:
2 s adjuvansom AS04, koji sadržava:
2adsorbed on aluminium hydroxide (0.5 mg Al3+)
2adsorbirano na aluminijevu hidroksidu (0,5 mg Al3+)
2adsorbed on aluminium hydroxide, hydrated (Al(OH)3) 0.5 milligrams Al3+ in total
2 adsorbiran na aluminijev hidroksid, hidratizirani (Al(OH)3) ukupno 0,5 mgAl3+
2Adsorbed on aluminium hydroxide, hydrated 0.025 milligrams Al3+ 3Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology 4Adsorbed on aluminium phosphate 0.2 milligrams Al3+
2 adsorbiran na aluminijev hidroksid, hidratizirani 0,025 miligrama Al3+ 3 proizveden tehnologijom rekombinantne DNK na stanicama kvasca (Saccharomyces cerevisiae) 4 adsorbiran na aluminijev fosfat 0,2 miligrama Al3+
2Adsorbed on aluminium hydroxide, hydrated 0.05 milligrams Al3+ 3Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology 4Adsorbed on aluminium phosphate 0.4 milligrams Al3+
2adsorbiran na aluminijev hidroksid, hidratiziran 0,05 miligrama Al3+ 3proizveden tehnologijom rekombinantne DNA na stanicama kvasca (Saccharomyces cerevisiae) 4adsorbiran na aluminijev fosfat 0,4 miligrama Al3+
2Adsorbed on aluminium hydroxide, hydrated 0.05 milligrams Al3+ 3Produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology 4Adsorbed on aluminium phosphate, 0.4 milligrams Al3+
2adsorbiran na aluminijev hidroksid, hidratiziran, 0,05 miligrama Al3+ 3proizveden tehnologijom rekombinantne DNA na stanicama kvasca (Saccharomyces cerevisiae) 4adsorbiran na aluminijev fosfat, 0,4 miligrama Al3+
2adsorbed on aluminium phosphate (0.5 milligrams Al3+ in total)
2adsorbiran na aluminijev fosfat (0,5 miligrama Al3+ ukupno)
2adsorbed on aluminium phosphate (0.5 milligrams Al3+ in total)
2adsorbirano na aluminijev fosfat (0,5 miligrama Al3+ukupno)
2Adverse reaction occurred both during the treatment phase and on the day of screening
2Nuspojava koja se pojavila tijekom faze liječenja i na dan probira
2all subjects seronegative prior to vaccination
2svi ispitanici koji su prije cijepljenja bili seronegativni
2Based on a logistic regression.
2Temeljeno na logističkoj regresiji.
2c Withdraw exactly 19 mL of the solution and unscrew the syringe.
2c Izvucite točno 19 ml otopine i odvijte štrcaljku.
2CFU – colony forming units
2 CFU – jedinice koje stvaraju kolonije
2D barcode carrying the unique identifier code
Sadrži 2D barkod s jedinstvenim identifikatorom.
2D barcode carrying the unique identifier included
Sadrži je 2D barkod s jedinstvenim identifikatorom.
2D barcode carrying the unique identifier included.
2D barkod koji nosi jedinstvenu identifikacijsku oznaku je uključen.
2D barcode carrying the unique identifier included.
<Sadrži 2D barkod s jedinstvenim identifikatorom.>
2D barcode carrying the unique identifier included.
Sadrţi 2D barkod s jedinstvenim identifikatorom.
2D barcode carrying the unique identifier included.
Sadrži 2D barcode s jedinstvenim identifikatorom.
2D barcode carrying the unique identifier included.
Sadrži 2D barkod s jedinstvenim idenitifikatorom.
2D barcode carrying the unique identifier included.
Sadrži 2D barkod s jedinstvenim identifikatorom..
2D barcode carrying the unique identifier included.
Sadrži2D barkod s jedinstvenim identifikatorom.
2D barcode carrying the unique identifier included. [outer packaging only]
Sadrži 2D barkod s jedinstvenim identifikatorom.[samo vanjsko pakiranje]
2Estimated median survival
2 procijenjeni medijan preživljenja
2Fatalities due to sepsis have been reported in patients treated with topotecan (see section 4.4).
2Smrtni ishodi zbog sepse zabilježeni su u bolesnika koji su liječeni topotekanom (vidjeti dio 4.4).
2Fifty percent of subjects were on insu
ward): Prijenos posljednjih zabilježen bno)
2Fifty percent of subjects were on insulin monotherapy at baseline; 50% were on 1 or 2 oral glucose-lowering medicinal product(s) in addition to insulin: Of this latter group, 80% were on metformin alone, 12% were on metformin plus sulphonylurea therapy, and the rest were on other oral glucose-lowering medicinal products.
2 Pedeset posto ispitanika je na početku liječenja primalo inzulin; 50% ih je uz inzulin je primalo 1 ili 2 oralna lijeka za snižavanje razine glukoze: u potonjoj je skupini 80% ispitanika primalo samo metformin, 12% metformin i sulfonilureju, a ostali su primali druge oralne lijekove za snižavanje razine glukoze.